Welcome to our dedicated page for Alcon Ordinary Shares news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon Ordinary Shares stock.
Alcon Inc. Ordinary Shares (symbol: ALC) is a premier American-Swiss healthcare company headquartered in Geneva, Switzerland, and incorporated in Fribourg, Switzerland. Renowned globally for its eye care products, Alcon excels in vision care and surgical segments, making it a leader in the eye care industry. Having spun off from Novartis in April 2019, Alcon now independently operates to enhance the quality of life through innovative vision products.
Alcon’s vision care segment includes a wide range of products such as contact lenses, lens care solutions, and ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon boasts significant control over the U.S. contact lens market. Their surgical segment offers advanced solutions like intraocular lenses (IOLs), ophthalmic surgical equipment, and consumables used during surgeries. Notable products include the Centurion phacoemulsification device and the Clareon, PanOptix, and Vivity IOLs.
Recently, Alcon launched the Clareon Vivity, which is the world’s first non-diffractive extended depth of focus (EDOF) intraocular lens. This innovative IOL incorporates wavefront-shaping technology, offering superior visual outcomes for cataract patients seeking presbyopia correction. The Clareon platform enhances Alcon's portfolio, which already includes the highly successful PanOptix lenses.
Financially, Alcon has shown robust growth. For Q4 2023, Alcon's sales reached $2.3 billion, marking an 8% increase from the previous year. Diluted EPS was $0.86, reflecting a 78% increase, and core diluted EPS was $0.70, up 67%. Alcon also reported a strong cash flow, with $937 million generated from operating activities in the first nine months of 2023.
Alcon's dedication to innovation and quality in eye care is further evidenced by its extensive research and development initiatives. The company engages in partnerships with eye care professionals and offers educational resources through the Alcon Experience Academy. Through consistent advancements and a customer-centric approach, Alcon continues to lead in enhancing sight and improving lives globally.
Alcon (NYSE: ALC) has announced the launch of the Clareon Toric intraocular lens, designed for U.S. cataract patients with astigmatism, featuring advanced stability technology. This product completes the Clareon Collection, which includes various IOL options. Additionally, Alcon will showcase its Fidelis Virtual Reality Surgical Simulator and patient engagement tools at the upcoming AAO 2022 conference in Chicago. Studies presented will highlight the effectiveness and patient satisfaction associated with Alcon's products, supporting their commitment to innovative eye care solutions.
Alcon has announced a definitive merger agreement to acquire Aerie Pharmaceuticals for approximately $770 million. The transaction is expected to enhance Alcon's capabilities in the $20 billion global ophthalmic pharmaceutical segment by adding products like Rocklatan® and Rhopressa®. The acquisition is anticipated to be accretive to Alcon's core diluted EPS in 2024. Aerie's glaucoma franchise net product revenue is projected at $130-140 million for 2022, with the transaction expected to close in Q4 2022, pending shareholder and regulatory approvals.
Alcon reported strong second quarter 2022 sales of $2.2 billion, a 5% increase from the previous year, and a significant 10% rise in constant currency. Though diluted earnings per share fell 3% to $0.30, core diluted EPS rose 13% to $0.63. The company's outlook for the full year was updated to net sales between $8.6 to $8.8 billion, reflecting consistent core operating margins but reduced expectations for core diluted EPS growth. Despite challenges from currency fluctuations, Alcon remains focused on new products and profitability improvements.
Alcon has launched a new campaign featuring Cooper Kupp to promote Pataday Once Daily Relief Extra Strength, an over-the-counter solution for eye allergies. Kupp shares his own experiences battling eye allergies, emphasizing the product's effectiveness in providing 24-hour relief with just one drop. Approximately 66 million Americans suffer from ocular allergies, yet only 9 million use allergy eye drops. The campaign aims to raise awareness of Pataday's benefits through multimedia content and partnerships with social media influencers, encouraging allergy sufferers to seek relief.
Alcon Inc. (NYSE: ALC) announced a public offering of EUR 500 million in 2.375% senior notes due 2028. The offering will be conducted by Alcon Finance B.V., a wholly-owned subsidiary, and guaranteed by Alcon Inc. The notes are set to close on May 31, 2022, pending customary conditions. Proceeds will be used for general corporate purposes, including refinancing existing debt. The notes will also be listed on the Luxembourg Stock Exchange's Euro MTF.
Alcon, a leader in eye care, has announced the acquisition of EYSUVIS® and INVELTYS® eye drops from Kala Pharmaceuticals for an upfront payment of $60 million. EYSUVIS, approved for treating acute dry eye disease, complements Alcon's Systane family of products, enhancing treatment options for over 30 million affected individuals in the U.S. This strategic move is expected to strengthen Alcon's position in the growing dry eye category and is anticipated to close in Q3 2022, pending regulatory approval. 2021 revenues for EYSUVIS and INVELTYS were $6.3 million and $4.9 million, respectively.
Alcon reported strong Q1 2022 sales of $2.2 billion, reflecting a 14% increase on a reported basis and 18% in constant currency year over year. Surgical and Vision Care segments both contributed to double-digit growth, with Surgical sales reaching $1.3 billion. The diluted earnings per share is $0.34, doubling from the previous year. Operating margin improved to 11.3%, while the core operating margin rose to 20.6%. Despite inflationary pressures, the company raised its constant currency growth outlook for 2022 to 9% to 11%.
Alcon Inc. (NYSE: ALC) reported the successful approval of all resolutions during its 2022 Annual General Meeting (AGM), held amid ongoing COVID-19 concerns. A total of 339,496,103 shares were represented, accounting for 69.05% of eligible votes. Key outcomes include the election of Dr. Raquel C. Bono to the Board, re-election of current Board members, and approval for a gross dividend of CHF 0.20 per share. Shareholders also agreed on the compensation amounts for the Board and the Executive Committee for the upcoming term.
Alcon (NYSE: ALC) announced key findings regarding its SMARTCataract application at ASCRS 2022, showcasing significant time savings in cataract surgery workflows. The updated SMARTCataract now integrates with the ORA SYSTEM using VerifEye+, enhancing connectivity with surgical equipment. A study led by Dr. Zachary Zavodni revealed that SMARTCataract can save up to 13.8 minutes in post-refractive patients compared to traditional methods. Alcon aims to improve patient outcomes through its digital health solutions designed for ophthalmic practices.
FAQ
What is the current stock price of Alcon Ordinary Shares (ALC)?
What is the market cap of Alcon Ordinary Shares (ALC)?
What does Alcon Inc. specialize in?
When did Alcon become an independent company?
What are Alcon’s major product brands in the vision care segment?
What significant recent product has Alcon launched?
How did Alcon perform financially in Q4 2023?
What educational resources does Alcon offer?
Where is Alcon Inc. headquartered?
What segments does Alcon operate in?
How has Alcon shown its commitment to innovation?
Who are the primary beneficiaries of Alcon's products?
